Mobile

Randomised, double-blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast can...

Update Il y a 4 ans
Reference: EUCTR2012-003187-44

Randomised, double-blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The main objective of this trial is to evaluate the benefit of adding 2 years everolimus treatment to standard adjuvant endocrine treatments in patients who remain free of disease, with high risk of relapse.

Inclusion criteria

  • Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

Links